ImmunoGen Inc.
About ImmunoGen Inc.
ImmunoGen is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its proprietary antibody-drug conjugate (ADC) technology. The Company's lead product candidate, mirvetuximab soravtansine, is being advanced to Phase 3 testing for FRα-positive platinum-resistant ovarian cancer, and is also in Phase 1b/2 testing in combination regimens for earlier-stage disease. The Company's ADC technology is used in three other clinical-stage ImmunoGen product candidates, in Roche's marketed product, Kadcyla®, and in programs in development by partners Amgen, Bayer, Biotest, CytomX, Lilly, Novartis, Sanofi and Takeda.
633 articles about ImmunoGen Inc.
-
The license and option deal, for an undisclosed amount, seeks to develop potentially first-in-class antibody-drug conjugate candidates against different oncology targets.
-
ImmunoGen Announces Multi-Target License and Option Agreement with ImmunoBiochem to Develop Next-Generation Antibody-Drug Conjugates
7/24/2023
ImmunoGen, Inc. announced a multi-target license and option agreement to research novel, first-in-class ADCs with ImmunoBiochem Corporation, a privately-held biopharmaceutical company focused on the discovery of unique tumor targets and development of novel biological therapeutics.
-
ImmunoBiochem Announces Multi-Target License and Option Agreement with ImmunoGen to Develop Next-Generation Antibody-Drug Conjugates
7/24/2023
ImmunoBiochem Corporation announced a multi-target license and option agreement with ImmunoGen, Inc., a leader in the expanding field of antibody-drug conjugates, to advance novel, first-in-class ADCs.
-
ImmunoGen Announces Conference Call to Discuss Its Second Quarter 2023 Operating Results
7/17/2023
ImmunoGen Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, announced that the Company will host a conference call at 8:00 a.m. ET on Monday, July 31, 2023 to discuss its second quarter 2023 operating results.
-
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 03, 2023
7/3/2023
ImmunoGen, Inc. announced that the compensation committee of the Company’s Board of Directors approved, effective as of June 30, 2023, grants of non-qualified stock options to purchase 32,300 shares of its common stock and restricted stock units covering 16,150 shares of its common stock under the Inducement Plan to three new employees.
-
ImmunoGen Presents Updated Findings from CADENZA Trial of Pivekimab Sunirine in Blastic Plasmacytoid Dendritic Cell Neoplasm at EHA 2023 Congress
6/9/2023
ImmunoGen Inc. announced updated data from an interim analysis of the Phase 2 CADENZA trial of pivekimab sunirine in patients with frontline and relapsed/refractory blastic plasmacytoid dendritic cell neoplasm.
-
ELAHERE® Demonstrates 35% Reduction in the Risk of Disease Progression or Death Versus Chemotherapy in FRα-Positive Platinum-Resistant Ovarian Cancer
6/4/2023
ImmunoGen Inc. announced detailed results from the Phase 3 confirmatory MIRASOL trial evaluating the safety and efficacy of ELAHERE® compared to chemotherapy in patients with folate receptor alpha -positive platinum-resistant ovarian cancer.
-
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 01, 2023
6/1/2023
ImmunoGen, Inc. announced that the compensation committee of the Company’s Board of Directors approved, effective as of May 31, 2023, grants of a non-qualified stock option award to purchase 15,600 shares of its common stock and restricted stock units covering 7,800 shares of its common stock under the Inducement Plan to one new employee.
-
ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming Jefferies Healthcare Conference
5/24/2023
ImmunoGen, Inc. announced that Mark Enyedy, President and CEO, and Anna Berkenblit, Chief Medical Officer, will participate in a fireside chat at the upcoming Jefferies Healthcare Conference in New York, NY.
-
ImmunoGen Announces Results from the Phase 3 MIRASOL Trial Selected as Late-Breaking Presentation for ASCO 2023 Annual Meeting
5/9/2023
ImmunoGen, Inc. announced that results from the Phase 3 confirmatory MIRASOL trial evaluating the safety and efficacy of ELAHERE® compared to chemotherapy in patients with folate receptor alpha -positive platinum-resistant ovarian cancer, have been selected for a late-breaking oral presentation at the 2023 American Society of Clinical Oncology Annual Meeting taking place June 2-6, 2023 in Chicago, Illinois.
-
ImmunoGen Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares - May 09, 2023
5/9/2023
ImmunoGen, Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, announced the closing of its previously announced underwritten public offering of 29,900,000 shares of its common stock, which reflects the exercise in full by the underwriters of their option to purchase up to 3,900,000 additional shares of common stock.
-
ImmunoGen Announces Pricing of Upsized Public Offering of Common Stock - May 05, 2023
5/5/2023
ImmunoGen Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, announced the pricing of an underwritten public offering of 26,000,000 shares of its common stock at a price of $12.50 per share, before underwriting discounts and commissions.
-
Data from Phase III confirmatory MIRASOL trial show antibody-drug conjugate boosts survival in platinum-resistant ovarian cancer, setting the stage for full approval by the FDA.
-
ELAHERE® Demonstrates Overall Survival Benefit in the Phase 3 MIRASOL Trial in Patients with FRα-Positive Platinum-Resistant Ovarian Cancer
5/3/2023
ImmunoGen Inc. (Nasdaq: IMGN) today announced positive top-line data from the Phase 3 confirmatory MIRASOL trial (GOG 3045/ENGOT OV-55) evaluating the safety and efficacy of ELAHERE® (mirvetuximab soravtansine-gynx) compared to chemotherapy in patients with folate receptor alpha (FRα)-positive platinum-resistant ovarian cancer who have received one to three prior lines of therapy.
-
ImmunoGen Announces Proposed Public Offering of Common Stock - May 03, 2023
5/3/2023
ImmunoGen Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, announced that it intends to offer and sell, subject to market and other conditions, $200 million of shares of its common stock in an underwritten public offering.
-
ImmunoGen Reports Recent Progress and First Quarter 2023 Financial Results
4/28/2023
ImmunoGen, Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, reviewed recent progress in the business and reported financial results for the quarter ended March 31, 2023.
-
ImmunoGen Appoints Isabel Kalofonos as Senior Vice President and Chief Commercial Officer
4/24/2023
ImmunoGen, Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, announced that Isabel Kalofonos has been appointed Senior Vice President and Chief Commercial Officer.
-
ImmunoGen Announces Conference Call to Discuss Its First Quarter 2023 Operating Results
4/13/2023
ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, April 28, 2023 to discuss its first quarter 2023 operating results.
-
ImmunoGen Announces Non-Dilutive Term Loan Financing for Up to $175 Million with Pharmakon Advisors
4/6/2023
ImmunoGen, Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, announced it has entered into a term loan financing facility for up to $175 million with entities managed by Pharmakon Advisors, LP.
-
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 03, 2023
4/3/2023
ImmunoGen, Inc. announced that on March 31, 2023, the Compensation Committee of the Company’s Board of Directors approved, in aggregate, grants of non-qualified stock option awards to purchase 106,600 shares of its common stock and restricted stock units covering 7,800 shares of its common stock to three new employees under the ImmunoGen, Inc. Inducement Equity Incentive Plan, as amended.